Influenza Vaccine Responses

1
Influenza Vaccine Responses

• Roland A. Levandowski, M.D.
• Division of Viral Products

Prepared for Vaccines and Related Biological
Products Advisory Committee 16-17 February 2005
2
Serum Panels for Serologies
1. ALAN HAMPSON ADULT A/NEW CALEDONIA/20/99-LIKE
(H1N1) WHO, AUSTRALIA ELDER A/WYOMING/3/2003
(H3N2) B/BRISBANE/32/2002   2. JOHN WOOD,
PH.D ADULT A/NEW CALEDONIA/20/99 (H1N1) NIBSC,
ENGLAND ELDER A/WYOMING/3/2003 (H3N2)
B/JIANGSU/10/2003   3. TAKATO ODIGARI,
PH.D. ADULT A/NEW CALEDONIA/20/99-LIKE (H1N1)
WHO, JAPAN ELDER A/WYOMING/3/2003 (H3N2)
B/SHANGHAI/361/2003
3
Serum Panels for Serologies
    4. STEFAN GRAVENSTEIN, M.D. ADULT A/NEW
CALEDONIA/20/99 (H1N1) EASTERN VIRGINIA
ELDER A/WYOMING/3/2003 (H3N2) MEDICAL
SCHOOL CHILD B/JIANGSU/10/2003   5. WILLIAM
KOCH, M.D. CHILD A/NEW CALEDONIA/20/99
(H1N1) VIRGINIA COMMONWEALTH A/WYOMING/3/2003 U
NIVERSITY B/JIANGSU/10/2003
4
ANTIGENS FOR SEROLOGIES (H1)

• VACCINE STRAIN
• A/NEW CALEDONIA/20/99 (H1N1)
• REPRESENTATIVE CURRENT STRAINS
• A/BANGKOK/1544/2004 (H1N1)
• A/FLORIDA/4/2004 (H1N1)
• A/NETHERLANDS/128/2004 (H1N1)
• A/NEW CALEDONIA/9/2004 (H1N1)
• A/OKINAWA/42/2004 (H1N1)
• A/SAITAMA/78/2004 (H1N1)
• A/SINGAPORE/14/2004 (H1N1)

5
HI ANTIBODY RESPONSES TO THE H1
COMPONENT2004-2005 INFLUENZA VACCINEADULT
POPULATION (CBER)
6
HI ANTIBODY RESPONSES TO THE H1
COMPONENT2004-2005 INFLUENZA VACCINEELDERLY
POPULATION (NIBSC)
7
HI ANTIBODY RESPONSES TO THE H1
COMPONENT2004-2005 INFLUENZA VACCINEPEDIATRIC
POPULATION (CDC AND CBER)
8
A/NEW CALEDONIA/20/99 VACCINESSUMMARY
TABLEVIRUSES WITH gt 50 GMT REDUCTION
9
ANTIGENS FOR SEROLOGIES (H3)

• VACCINE STRAIN
• A/WYOMING/3/2003
• REPRESENTATIVE CURRENT STRAINS
• A/BANGKOK/1563/2004
• A/CALIFORNIA/7/2004
• A/OSAKA/36/2004
• A/OSLO/8/2004
• A/SHANTOU/1219/2004
• A/SINGAPORE/36/2004
• A/SINGAPORE/37/2004
• A/TENNESSEE/6/2004
• A/TOKYO/1035/2004
• A/VICTORIA/523/2004

10
HI ANTIBODY RESPONSES TO THE H3
COMPONENT2004-2005 INFLUENZA VACCINEADULT
POPULATION ( CDC )
11
HI ANTIBODY RESPONSES TO THE H3
COMPONENT2004-2005 INFLUENZA VACCINEELDERLY
POPULATION (NIBSC)
12
HI ANTIBODY RESPONSES TO THE H3
COMPONENT2004-2005 INFLUENZA VACCINEPEDIATRIC
POPULATION (CDC AND CBER)
13
A/WYOMING/3/2003 VACCINESSUMMARY TABLEVIRUSES
WITH gt 50 GMT REDUCTION
14
ANTIGENS FOR SEROLOGIES (B)

• VACCINE STRAIN
• B/BRISBANE/32/2002
• B/JIANGSU/10/2003
• REPRESENTATIVE CURRENT STRAINS
• B/HAWAII/13/2004
• B/PHITSANULOK/2053/2004
• B/COLORADO/4/2004
• B/FLORIDA/7/2004
• B/FUJIAN/430/2004 HONG KONG/330-LIKE
• B/LISBON/1/2004 SHANGHAI/361-LIKE
• B/SHIZUOKA/2/2004
• B/SHIZUOKA/58/2004
• B/VICTORIA/501/2004

15
HI ANTIBODY RESPONSES TO THE B COMPONENT2004-2005
INFLUENZA VACCINEADULT POPULATION (CDC)
16
HI ANTIBODY RESPONSES TO THE B COMPONENT2004-2005
INFLUENZA VACCINEELDERLY POPULATION (AUS)
17
HI ANTIBODY RESPONSES TO THE B COMPONENT2004-2005
INFLUENZA VACCINEPEDIATRIC POPULATION (CDC AND
CBER)
18
B/SHANGHAI/361/2002-LIKE VACCINESSUMMARY
TABLEVIRUSES WITH gt 50 GMT REDUCTION
19
Influenza Vaccine ResponsesSummary

• Studies with sera collected after immunization
  with current vaccines show that
• Representative influenza A (H1N1) viruses are
  well-inhibited
• A/California/7/2004 (H3N2)-like viruses are
  poorly inhibited compared to the vaccine strain
• B/Shanghai/361/2002-like viruses are reasonably
  well-inhibited but B/Hong Kong/330/2001-like
  viruses are less well inhibited than the vaccine
  strains